Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03936985 · ClinicalTrials.gov registry record
Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool
A clinical trial, sponsored by University of Utah.
- Completed
- Registry status
- 1,464
- Enrollment target
NCT03936985: Completed study, sponsored by University of Utah.
NCT03936985 is a clinical trial that has completed, run by University of Utah. The registered enrollment target is 1,464 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03936985 has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- 1,464 participants
- Enrollment target
Study Summary
The goal of the study is to validate a Prescription Drug Monitoring Program-based opioid risk metric to discriminate between low, moderate, and high-risk opioid use disorder. The World Health Organization Alcohol, Smoking, and Substance Involvement Screening Test (WHO ASSIST) will be used as the gold standard instrument that defines patient risk levels. No intervention or hypothesis will be tested.
Primary Outcome
To assess the validity of the PDMP Narcotic Score, the AUC (Area Under the Curve) was used. AUC ranges in value from 0 to 1. A model whose predictions are 100% wrong has an AUC of 0.0; one whose predictions are 100% correct has an AUC of 1.0. And when AUC is 0.5, it means the model has no means of separating between the different groups. For this study, the closer to 1.0 the more similar the PDMP Narcotic Score is to the WHO ASSIST.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,464 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2023-05-31 |
What the finished NCT03936985 record still lists
NCT03936985 is an observational study that tracks outcomes without assigning an intervention. Its 1,464 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03936985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03936985 about?
NCT03936985 is a clinical study titled "Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool". The goal of the study is to validate a Prescription Drug Monitoring Program-based opioid risk metric to discriminate between low, moderate, and high-risk opioid use disorder. The World Health Organization Alcohol, Smoking, and Substance Involvement Screening Test (WHO ASSIST) will be used as the gol...
What is the current status of trial NCT03936985?
This trial is currently completed. The enrollment target is 1,464 participants. The study started on 2019-11-04. Estimated completion is 2023-05-31.
Who is sponsoring clinical trial NCT03936985?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI